Bird Rock Bio Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Bird Rock Bio Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011838
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bird Rock Bio Inc (Bird Rock Bio), formerly RuiYi Inc is a clinical stage biopharmaceutical company that develops immuno-inflammatory regulators. The company’s products under development include RYI-018 is a peripheral antagonist antibody to cannabinoid receptor 1 intended for the treatment of nonalcoholic steatohepatitis, fibrotic and metabolic diseases. Its Gerilimzumab, an anti IL-6 antibody indicated for moderate to severe rheumatoid arthritis, inflammatory and autoimmune diseases. Bird Rock Bio provides therapeutic antibodies, with clinical and commercial differentiation, against biologic targets. The company operates through research institutes and universities for its activities. Bird Rock Bio is headquartered in La Jolla, California, the US.

Bird Rock Bio Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Bird Rock Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
RuiYi Raises US$15 Million In Series B Financing 10
Anaphore Secures US$0.15 Million In Venture Financing 12
Partnerships 13
Bird Rock Bio Enters into agreement with GE Healthcare 13
Janssen Pharma Enters into Partnership with Bird Rock Bio 14
RuiYi Enters into Agreement with iHuman Institute to Develop Novel Antibodies 15
CMC Biologics Enters Into Co-Development Agreement With RuiYi For RYI-008 Cell Line 16
Licensing Agreements 17
Bird Rock Bio Enters into Licensing Agreement with arGEN-X for ARGX-109 17
RuiYi Enters Into Licensing Agreement With Genor BioPharma For RYI-008 19
Bird Rock Bio Inc – Key Competitors 20
Bird Rock Bio Inc – Key Employees 21
Bird Rock Bio Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Clinical Trials 23
Jan 11, 2017: Bird Rock Bio Receives Approval to Start First in Human Clinical Trial for Namacizumab 23
Jan 03, 2017: Bird Rock Bio Receives Approval from ANVISA and CONEP to Initiate the First Phase 2 Study in Brazil of Gerilimzumab for Rheumatoid Arthritis 24
Oct 27, 2016: Bird Rock Bio Submits Clinical Trial Authorization for the First in Human Clinical Trial for Namacizumab 25
Mar 15, 2016: argenx’s Partner Bird Rock Bio Demonstrates Potential for Gerilimzumab, A Novel SIMPLE Antibody Against IL-6 to Treat Rheumatoid Arthritis 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Key Facts 2
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Bird Rock Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Bird Rock Bio Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
RuiYi Raises US$15 Million In Series B Financing 10
Anaphore Secures US$0.15 Million In Venture Financing 12
Bird Rock Bio Enters into agreement with GE Healthcare 13
Janssen Pharma Enters into Partnership with Bird Rock Bio 14
RuiYi Enters into Agreement with iHuman Institute to Develop Novel Antibodies 15
CMC Biologics Enters Into Co-Development Agreement With RuiYi For RYI-008 Cell Line 16
Bird Rock Bio Enters into Licensing Agreement with arGEN-X for ARGX-109 17
RuiYi Enters Into Licensing Agreement With Genor BioPharma For RYI-008 19
Bird Rock Bio Inc, Key Competitors 20
Bird Rock Bio Inc, Key Employees 21

★海外企業調査レポート[Bird Rock Bio Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Trinity Health:企業の戦略的SWOT分析
    Trinity Health - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Pharmerica Corp:企業の戦略的SWOT分析
    Pharmerica Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • National Fuel Gas Co (NFG):企業の財務・戦略的SWOT分析
    National Fuel Gas Co (NFG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Diehl Stiftung & Co. KG:企業の戦略・SWOT・財務情報
    Diehl Stiftung & Co. KG - Strategy, SWOT and Corporate Finance Report Summary Diehl Stiftung & Co. KG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Canon Inc.:企業の戦略・SWOT・財務情報
    Canon Inc. - Strategy, SWOT and Corporate Finance Report Summary Canon Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Credit Du Nord Sa
    Credit Du Nord Sa - Strategy, SWOT and Corporate Finance Report Summary Credit Du Nord Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • New Zealand Energy Corp (NZ):企業の財務・戦略的SWOT分析
    Summary New Zealand Energy Corp (New Zealand Energy), formerly East Coast Energy Ventures Ltd is an oil and gas company. The company carries out the business of production, development and exploration of conventional and unconventional oil and natural gas prospects in New Zealand. It acquires strate …
  • Cree, Inc.:戦略・SWOT・企業財務分析
    Cree, Inc. - Strategy, SWOT and Corporate Finance Report Summary Cree, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Xtract Resources Plc (XTR):企業の財務・戦略的SWOT分析
    Summary Xtract Resources Plc (Xtract Resources), formerly Xtract Energy plc is a mining and mineral exploration and development company that offers mineral resources. The company acquires, explores, manages, operates, produces, mines, extracts, and develops gold and mineral resource deposit properti …
  • RPC Group Plc (RPC):企業の財務・戦略的SWOT分析
    RPC Group Plc (RPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Barclaycard:企業の戦略・SWOT・財務分析
    Barclaycard - Strategy, SWOT and Corporate Finance Report Summary Barclaycard - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Editas Medicine Inc (EDIT):製薬・医療:M&Aディール及び事業提携情報
    Summary Editas Medicine Inc (Editas Medicine) formerly Gengine Inc, is a discovery stage biotechnology company that develops genome level treatments for rare diseases. The company is developing a proprietary genome editing platform based on its in-licensed clustered regularly interspaced short palin …
  • EDP – Energias do Brasil SA:企業の戦略・SWOT・財務情報
    EDP - Energias do Brasil SA - Strategy, SWOT and Corporate Finance Report Summary EDP - Energias do Brasil SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • African Development Bank Group:企業の戦略的SWOT分析
    African Development Bank Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Croma-Pharma GmbH-医療機器分野:企業M&A・提携分析
    Summary Croma-Pharma GmbH (Croma Pharma) is a pharmaceutical company which focuses on the development and commercialization of drugs in the field of aesthetic dermatology. It offers princess injectables, princess skincare, and princess lift products. The company’s princess skincare products comprise …
  • Cascade Metrix LLC:企業の製品パイプライン分析
    Summary Cascade Metrix LLC (CMI) is a medical technology company that offers automated POC blood analyzer for critical care. The company offers novel micro-volume IV extension kits, and automated glucose monitoring systems, among others. It also provides a revolutionary ex vivo blood analysis system …
  • Sunshine Oilsands Ltd (2012):石油・ガス:M&Aディール及び事業提携情報
    Summary Sunshine Oilsands Ltd (Sunshine Oilsands) is an oil and gas company that develops holdings of oil sands and PN&G leases. The company owns and controls oil sands leases. Its properties include Thickwood, West Ells, Muskwa, Harper, Legend Lake and Portage, among others. Sunshine Oilsands also …
  • Motif Bio Plc (MTFB):製薬・医療:M&Aディール及び事業提携情報
    Summary Motif Bio Plc (Motif Bio), formerly Motif Bio Ltd, is a clinical-stage biopharmaceutical company that focuses on the development of novel antibiotics to treat patients with infections caused by multi-drug resistant bacteria. The company develops Iclaprim, a targeted Gram-positive1 antibiotic …
  • MagForce AG (MF6):企業の財務・戦略的SWOT分析
    Summary MagForce AG (MagForce) is a medical device company that offers nanotechnology-based therapy for cancer treatment. The company’s products include NanoActivator, NanoTherm, NanoPlan and NanoTherm Therapy. Its NanoActivator creates a magnetic field that can be used to treat tumors in all areas …
  • Cognition Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Cognition Therapeutics Inc (CogRx) is a drug discovery and development company that discovers and develops small molecule therapeutics to improve the lives of individuals with Alzheimer’s disease and other neurocognitive disorders. The company uses its proprietary biology and chemistry platf …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆